In the current environment, the large commitments that biotech and pharmaceutical companies must make to fully leverage late-stage pipelines, often limit the resources needed to advance early-phase candidates. Companies are forced to make trade-off decisions without adequate clinical data, and compounds are often “shelved” without compelling rationale one way or the other. Other compounds may be de-prioritized, thereby hindering their progress towards meaningful clinical data. Among these compounds are assets of substantial but unrecognized medical and commercial value. Triphase is forming partnerships with major pharmaceutical and biotechnology companies and financial investors to advance such promising compounds with potential in oncology indications.